{
    "2019-12-23": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Pfizer Outpaces Stock Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "outpaces",
                        "stock market gains"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "HIV",
                        "CRL",
                        "FDA"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication",
                "features": {
                    "keywords": [
                        "Bristol-Myers",
                        "Revlimid",
                        "EU",
                        "nod",
                        "new indication"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program",
                "features": {
                    "keywords": [
                        "Theravance Biopharma",
                        "Pfizer",
                        "global license agreement",
                        "JAK inhibitor"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}